Xeljanz (Tofacitinib) FAQ: Generic Availability, Costs & Copay Assistance

If you’ve been prescribed Xeljanz (tofacitinib) for rheumatoid arthritis, ulcerative colitis, psoriatic arthritis, or ankylosing spondylitis, one of your first questions is almost certainly: How am I going to afford this?

With a retail price of nearly $9,000 per month without insurance, Xeljanz is one of the most expensive specialty medications on the market. But the number patients actually pay — especially with the right support — can be dramatically lower. And with generic tofacitinib on the horizon, the landscape is shifting fast.

We put together this FAQ to answer the questions our patients ask us most, straight from the specialists who help them navigate it every day.

“Cost is the first thing most patients bring up when they’re prescribed Xeljanz,” says Julia Kravtsova, PharmD, Head Patient Navigator at QuickRx Specialty Pharmacy. “The good news is that between copay assistance programs and the upcoming generic, patients have more options than they realize — they just need someone to help them find and access them.”

Is There a Generic for Xeljanz (Tofacitinib)?

Has the FDA approved a generic tofacitinib?

Yes — partially. The FDA approved a generic version of tofacitinib citrate tablets (5 mg and 10 mg immediate-release) in August 2025, with Ajanta Pharma Ltd among the first to receive approval. However, FDA approval alone does not mean the generic is available at your pharmacy right now.

Active patent protections and exclusivity rights can legally prevent manufacturers from selling a generic even after FDA approval. Xeljanz’s primary patent was expected to expire in December 2025, but a pediatric exclusivity extension has pushed the expected timeline for widely available generic tofacitinib to 2026. The situation is evolving rapidly, and broader availability is anticipated in the coming months.

Does Xeljanz XR (extended-release) have a generic?

No. The 2025 generic approval applies only to the immediate-release tofacitinib tablets (5 mg and 10 mg) — not to Xeljanz XR (11 mg or 22 mg extended-release). If you take Xeljanz XR, a generic equivalent is not currently available. Tofacitinib copay assistance programs remain the most effective way to reduce your costs right now.

When will generic tofacitinib be widely available?

Industry sources and rheumatology experts expect generic tofacitinib to become more broadly available in 2026 as patent exclusivity fully winds down. Tofacitinib is the first FDA-approved Janus kinase (JAK) inhibitor, and its generic market entry is being closely watched as a potential turning point in specialty drug affordability for the RA and IBD communities.

It’s worth noting that experts have raised important questions about whether pharmacy benefit managers (PBMs) — which often steer specialty prescriptions toward their own in-house pharmacies — may limit how accessible and affordable generic tofacitinib actually becomes for patients. At QuickRx, we’ll actively keep our patients informed as the landscape changes and help them access the most affordable option available.

Is generic tofacitinib the same as Xeljanz?

Yes. Generic tofacitinib contains the same active ingredient — tofacitinib citrate — at the same dosage and strength as brand-name Xeljanz. FDA-approved generics must demonstrate bioequivalence to the original drug, meaning they are absorbed the same way and produce the same clinical effect.

A word of caution: some online pharmacies claim to sell generic tofacitinib before it has been legally cleared for the US market. These medications may be counterfeit and potentially unsafe. Always obtain your medication through a licensed US specialty pharmacy and verify with your pharmacist before purchasing from any unfamiliar online source.

Will generic tofacitinib still require prior authorization?

Almost certainly, yes — at least initially. Tofacitinib is a specialty JAK inhibitor, and even generic versions are expected to require prior authorization from your insurance company. Insurance plans typically require documented failure of other treatments before approving JAK inhibitors. Your prescribing physician and specialty pharmacy will manage the prior authorization process on your behalf. At QuickRx, prior authorization support is included in our free patient navigation services — call (917) 830-2525 for help.

How Much Does Xeljanz Cost?

How much does Xeljanz cost without insurance?

Without insurance, Xeljanz is one of the most expensive specialty medications available. As of 2026, the average retail price for a 30-day supply of Xeljanz 5 mg immediate-release tablets is approximately $8,900–$9,000 per month. Xeljanz XR pricing is comparable.

The important thing to know: very few patients actually pay this price. Between manufacturer copay cards, patient assistance programs, and the support of a knowledgeable specialty pharmacy, most commercially insured patients pay significantly less — and many eligible patients pay $0.

How much does Xeljanz cost with insurance?

Your out-of-pocket cost with insurance depends on your specific plan, tier placement, and whether you’ve met your deductible. Xeljanz is typically placed in the highest specialty tier (Tier 4 or Tier 5) on most formularies, which means copays or coinsurance can still run into hundreds — or even thousands — of dollars per month even with solid commercial coverage.

This is exactly why tofacitinib copay assistance programs exist: to cover the gap between what your insurance pays and what you’d otherwise owe. Our patient navigators review your specific plan and identify every available program that applies to your situation.

Does prior authorization affect cost?

Yes. Xeljanz requires prior authorization on almost all insurance plans, and step therapy is also common — meaning your insurer may require you to demonstrate failure on other medications first. This process can delay access and add stress, but it’s navigable. QuickRx handles prior authorization on behalf of our patients at no charge. If your claim is denied, we support the appeals process as well.

How Does Tofacitinib Copay Assistance Work?

What is tofacitinib copay assistance and how does it work?

Tofacitinib copay assistance refers to financial support programs designed to help patients afford their Xeljanz prescription by reducing or eliminating out-of-pocket costs. These programs include manufacturer copay cards, independent charitable foundation grants, and patient assistance programs that work alongside your insurance coverage.

The manufacturer copay card program typically provides the most substantial savings for commercially insured patients. These programs cover the gap between what your insurance pays and your pharmacy cost, up to a maximum annual benefit amount. Eligible patients may pay as little as $0 per prescription.

“The copay card programs for Xeljanz can be genuinely life-changing for patients,” says Julia Kravtsova, PharmD. “We’ve seen patients go from panic about a $2,000 monthly bill to paying nothing — but you have to know what programs exist and how to apply correctly, which is what our team does every day.”

Who qualifies for Xeljanz copay assistance?

Eligibility depends on your insurance type and the specific program:

• Commercially insured patients: Generally eligible for manufacturer copay cards. Eligibility is typically not income-based.
• Medicare and Medicaid patients: Not eligible for manufacturer copay cards due to federal anti-kickback regulations, but may qualify for independent foundation grants, the Pfizer Patient Assistance Program, or Medicare Extra Help (Low Income Subsidy).
• Uninsured patients: May qualify for patient assistance programs that provide Xeljanz at no cost.

QuickRx conducts a comprehensive eligibility assessment for every patient and identifies all programs available for their specific situation — even layering multiple programs when permitted to maximize savings.

How do I apply for tofacitinib copay assistance?

The simplest way is to call QuickRx Specialty Pharmacy at (917) 830-2525 or complete the copay assistance request form on our website. A dedicated patient navigator will gather basic information about your insurance coverage and prescription, identify every program you qualify for, and handle the applications on your behalf. There is never any cost for this service.

Is there a fee for QuickRx’s copay assistance services?

No — never. QuickRx Specialty Pharmacy provides all copay assistance enrollment, application management, appeals support, and annual renewal assistance completely free of charge. Our goal is to make sure financial barriers never prevent a patient from accessing the medication they need.

What About Medicare Patients?

Does Medicare cover Xeljanz?

Medicare coverage for Xeljanz is more limited than commercial insurance. As an oral specialty medication, Xeljanz falls under Medicare Part D (not Part B). Approximately 84% of Medicare Part D plans cover Xeljanz, but it is generally classified as a Tier 5 drug — the most expensive tier — meaning out-of-pocket costs can still be substantial even with coverage.

Can Medicare patients get tofacitinib copay assistance?

Medicare patients cannot use manufacturer copay cards due to federal anti-kickback regulations — this is true for Xeljanz and all specialty medications. However, alternative assistance options do exist:

• Pfizer Patient Assistance Program (PAP): May provide Xeljanz at no cost to eligible Medicare patients who meet income requirements
• Independent charitable foundations: May provide grants to help cover costs for Medicare patients
• Medicare Extra Help / Low Income Subsidy (LIS): Federal program that helps Medicare beneficiaries with low income pay for Part D premiums, deductibles, and copays
• Medicare Prescription Payment Plan: As of January 2025, allows patients to spread out-of-pocket prescription costs over the calendar year rather than paying upfront

QuickRx patient navigators specialize in finding assistance for Medicare patients specifically. Call (917) 830-2525 — we’ll assess every available option for your situation.

Frequently Asked Questions

What conditions does Xeljanz treat?

Xeljanz (tofacitinib) is FDA-approved for moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis, active ankylosing spondylitis, and moderately to severely active ulcerative colitis — all in adults who have had an inadequate response or intolerance to one or more TNF blockers. It is also approved for polyarticular course juvenile idiopathic arthritis and psoriatic arthritis in pediatric patients aged 2 years and older.

How does Xeljanz work?

Xeljanz is a Janus kinase (JAK) inhibitor. It works by blocking JAK enzymes — intracellular proteins involved in triggering immune cell activity and inflammation. By inhibiting these enzymes, tofacitinib reduces the inflammatory response driving conditions like RA and ulcerative colitis.

What is the difference between Xeljanz and Xeljanz XR?

Xeljanz is the immediate-release (IR) formulation, taken twice daily (available as 5 mg and 10 mg tablets and a 1 mg/mL oral solution). Xeljanz XR is the extended-release formulation, taken once daily (available as 11 mg and 22 mg tablets). The two formulations are not interchangeable or substitutable — your prescriber will determine which is right for your condition and lifestyle.

Can Xeljanz be taken with food?

Yes — Xeljanz may be taken with or without food. However, Xeljanz XR extended-release tablets must be swallowed whole and intact; they should never be crushed, split, or chewed. The tablet shell of Xeljanz XR may occasionally appear in your stool — this is normal and does not mean the medication was not absorbed.

How long does Xeljanz take to work?

For rheumatoid arthritis and psoriatic arthritis, some patients begin to notice improvement within 2 weeks, though it may take up to 3–4 months for the full effect. For ulcerative colitis, most patients see symptom improvement within 2–8 weeks of starting induction therapy. Response times vary by individual and condition.

What are the most common side effects of Xeljanz?

The most common side effects include infections (20–22%), nasopharyngitis (3–14%), elevated LDL cholesterol (15–19%), headache (3–9%), diarrhea (3–5%), upper respiratory infections (4–7%), and herpes zoster/shingles (1–5%). Regular blood monitoring for cholesterol, blood counts, and liver function is required during treatment.

What are the serious warnings for Xeljanz?

Xeljanz carries a US Boxed Warning covering five serious risks: serious infections (including TB and opportunistic infections), increased mortality risk in RA patients over 50 with cardiovascular risk factors, malignancies (including lymphoma and skin cancers), major adverse cardiovascular events (MACE), and thrombosis (blood clots including DVT and pulmonary embolism). Discuss your individual risk factors with your prescriber.

Can I get Xeljanz if I have Medicare?

Yes, most Medicare Part D plans cover Xeljanz, though it is typically a high-tier drug with significant cost-sharing. Medicare patients are not eligible for manufacturer copay cards, but may qualify for the Pfizer Patient Assistance Program, independent foundation grants, or Medicare Extra Help. QuickRx can assess all available options for you — call (917) 830-2525.

Does Xeljanz interact with other medications?

Yes. Tofacitinib is metabolized primarily by CYP3A4 and CYP2C19. Strong CYP3A4 inhibitors (including fluconazole) can increase tofacitinib exposure and require dose reductions. Strong CYP3A4 inducers can decrease effectiveness. Xeljanz should never be combined with biologic DMARDs, or potent immunosuppressants like azathioprine, tacrolimus, or cyclosporine. Always share a complete medication list — including supplements and herbal products — with your prescriber and pharmacist.

What should I do if I can’t afford my Xeljanz prescription?

Contact QuickRx Specialty Pharmacy immediately at (917) 830-2525. Our patient navigators will conduct a free eligibility assessment, identify every copay assistance and patient assistance program available for your situation, and handle the applications on your behalf. Do not skip doses or discontinue treatment without speaking to your healthcare provider — there are options available to help you stay on therapy.

References

1. Xeljanz/Xeljanz XR (tofacitinib) Prescribing Information. Pfizer Inc; January 2026.
2. U.S. Food and Drug Administration. FDA Requires Warnings About Increased Risk of Serious Heart-Related Events, Cancer, Blood Clots, and Death for JAK Inhibitors. 2021.
3. American College of Rheumatology. Tofacitinib (Xeljanz). Updated April 2025.
4. Crohn’s & Colitis Foundation. Xeljanz (Tofacitinib).
5. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Rheumatoid Arthritis.
6. MedlinePlus. Tofacitinib.
7. LexiDrug™ via UpToDate® (Wolters Kluwer Health). Tofacitinib monograph. Last Updated 3/24/26.

This information is not intended to replace professional medical advice. Always consult your rheumatologist, gastroenterologist, or pharmacist for guidance specific to your Xeljanz treatment. For questions about tofacitinib copay assistance, contact QuickRx Specialty Pharmacy at (917) 830-2525.